3Chaires JB,Fox KR,Herrera JE,et al.Site and Sequence specificity of the daunomycin-DNA interaction[J].Biochemistry,1987,26(25):8227-8236.
4Dervan PR.Design of sequence-specifc DNA-binding molecules[J].Science,1986,232(4749):464-471.
5Lerman LS.Structural considerations in the interaction of DNA and acridines[J].J Mol Biol,1961,3(1):18-30.
6Lerman LS.Acridine mutagens and DNA structure[J].J Cell Physiol,1964,64(Suppl 1):S1-S18.
7Graves DE,Velea LM.Intercalative binding of small molecules to nucleic acids[J].Curr Org Chem,2000,4(9):915-929.
8Bischoff G,Hoffmann S.DNA-Binding of drugs used in medicinal therapies[J].Curr Med Chem,2002,9(3):321-348.
9Hooper DC.Clinical applications of quinolones[J].Biochim Biophys Acta,1998,1400(1-3):45-61.
10Zhang JL,Sharma PL,Li CJ,et al.Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I[J].Antimicrob Agents Chemother,1997,41(5):977-981.
